Taxane-based therapy is commonly applied in patients with advanced breast cancer (BC). It often accompanied serious symptomatic adverse events (AEs) which can deteriorate patients’ quality of life (QoL). Eribulin a non-taxane microtubule inhibitor respect to less AEs and prolonged overall survival. Here, we report the analysis QoL based on PRO before after initiating BC intolerant taxane-based ...

Taxanes have remained a cornerstone of breast cancer treatment over the past three decades, improving the lives of patients with both early- and late-stage disease. The purpose of this review is to summarize the current role of taxanes, including an albumin-bound formulation that enhances delivery of paclitaxel to tumors, in the management of metastatic breast cancer (MBC). Since the introducti...

OBJECTIVES To estimate the clinical effectiveness and cost-effectiveness of docetaxel and paclitaxel compared with non-taxane, anthracycline-containing chemotherapy regimens, for the adjuvant treatment of women with early-stage breast cancer. DATA SOURCES Major electronic databases were searched between October 2005 and February 2006. REVIEW METHODS A systematic review of the literature on ...

OBJECTIVE Docetaxel causes cell death through induction of apoptosis; however, cell death characteristics for docetaxel have not yet been fully elucidated. We examined the role of focal adhesion kinase (FAK) cleavage in docetaxel-mediated apoptosis. METHODS FAK degradation after treatment with docetaxel was determined in both taxane-sensitive (HeyA8 and SKOV3) and taxane-resistant (HeyA8-MDR ...

background: oral mucositis (om) remains the most common side effect of chemotherapy affects negatively on patients' quality of life. subjects and methods : convenience samples of patients who received chemotherapy were followed from first or second cycle of chemotherapy until om occurrence. we reviewed 75 female patients with breast cancer who received chemotherapy with mean age (47.2 sd ± 8.62...

•Treatment of sex-cord stromal tumors with carboplatin and taxane is both feasible and safe.•FOXL2 mutations account for approximately 50% of these tumors.•Carboplatin and taxane may afford a favorable outcome.

INTRODUCTION With the widespread use of sequential anthracycline/taxane-based chemotherapy for early-stage breast cancer, clinicians are becoming rapidly aware of toxicities associated with those regimens. Despite the low incidence reported in the literature of significant arthralgia and myalgia with those regimens, it is clinically evident that a substantial proportion of patients develop such...

The taxanes are used alone or in combination with anthracyclines or platinum drugs to treat breast and ovarian cancer, respectively. Taxanes target microtubules in cancer cells and modifiers of taxane sensitivity have been identified in vitro, including drug efflux and mitotic checkpoint proteins. Human epidermal growth factor receptor 2 (HER2/ERBB2) gene amplification is associated with benefi...

BACKGROUND We have previously shown that transducin-like enhancer of split 3 (TLE3) is associated with outcome specifically in patients with taxane-treated breast cancer and not in patients treated with anthracycline-based regimens without a taxane. The purpose of this study was to assess the association between TLE3 expression and recurrence in patients with ovarian carcinoma treated with a ta...

The clinical benefits provided by using combined taxanes and anthracyclines in first-line chemotherapy for metastatic breast carcinoma (MBC) remain uncertain. This meta-analysis compares the benefits of using a combination of anthracyclines along with taxanes versus using single-agent-based chemotherapeutic regimens in the treatment of MBC.Relevant clinical trials as well as abstracts from arti...